Review top news and interview highlights from the week ending December 17, 2021.
Welcome to GeneTherapyLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The findings, which were simultaneously reported in the New England Journal of Medicine, support beti-cel as a potentially curative, one-time treatment option for these patients.
Over half of patients in the fitusiran arm of the ATLAS-INH study had 0 treated bleeding events.
Scott Requadt, chief executive officer, Talaris Therapeutics, discussed the company’s goal to reprogram the immune system. He discussed the company’s approach and how the COVID-19 pandemic has exacerbated the unmet need in these indications.
The vice chair, Blood and Marrow Transplant and Cellular Immunotherapy Program, and co-leader, Immuno-Oncology, Moffitt Cancer Center, discussed the results of the phase 3 ZUMA-7 trial.
AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed safety findings from the phase 3 ALLELE study.